Clinical Effectiveness and Nephrotoxicity of Aerosolized Colistin Treatment in Multidrug-Resistant Gram-Negative Pneumonia
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Colistin (polymyxin E) is active against multidrug-resistant Gram-negative bacteria (MDR-GNB). However, the effectiveness of inhaled colistin is unclear. This study was designed to assess the effectiveness and safety of aerosolized colistin for the treatment of ventilator-associated pneumonia (VAP) caused by MDR-GNB. Methods: In this retrospective longitudinal study, we evaluated the medical records of 63 patients who received aerosolized colistin treatment for VAP caused by MDR-GNB in the medical intensive care unit (MICU) from February 2012 to March 2014. Results: A total of 25 patients with VAP caused by MDR-GNB were included in this study. The negative conversion rate was 84.6% after treatment, and acute kidney injury (AKI) occurred in 11 patients (44%, AKI group). The average length of MICU stay and colistin treatment- related factors, such as daily and total cumulative doses and administration period, were not significantly different between groups. In-hospital mortality tended to be higher in the AKI group (p = 0.07). Multivariate analysis showed that a body mass index less than 18 was an independent risk factor of mortality (odds ratio [OR] = 21.95, 95% confidence interval [CI] 1.59-302.23; p = 0.02). Notably, AKI occurrence was closely related to the administration of more than two nephrotoxic drugs combined with aerosolized colistin (OR = 15.03, 95% CI 1.40-161.76; p = 0.025) and septic shock (OR = 8.10, 95% CI 1.40-161.76; p = 0.04). Conclusions: The use of adjunctive aerosolized colistin treatment appears to be a relatively safe and effective option for the treatment of VAP caused by MDR-GNB. However, more research on the concomitant use of nephrotoxic drugs with aerosolized colistin will be necessary, as this can be an important risk factor of development of AKI.
Abstract
Background: Colistin (polymyxin E) is active against multidrug-resistant Gram-negative bacteria (MDR-GNB). However, the effectiveness of inhaled colistin is unclear. This study was designed to assess the effectiveness and safety of aerosolized colistin for the treatment of ventilator-associated pneumonia (VAP) caused by MDR-GNB. Methods: In this retrospective longitudinal study, we evaluated the medical records of 63 patients who received aerosolized colistin treatment for VAP caused by MDR-GNB in the medical intensive care unit (MICU) from February 2012 to March 2014. Results: A total of 25 patients with VAP caused by MDR-GNB were included in this study. The negative conversion rate was 84.6% after treatment, and acute kidney injury (AKI) occurred in 11 patients (44%, AKI group). The average length of MICU stay and colistin treatment- related factors, such as daily and total cumulative doses and administration period, were not significantly different between groups. In-hospital mortality tended to be higher in the AKI group (p = 0.07). Multivariate analysis showed that a body mass index less than 18 was an independent risk factor of mortality (odds ratio [OR] = 21.95, 95% confidence interval [CI] 1.59-302.23; p = 0.02). Notably, AKI occurrence was closely related to the administration of more than two nephrotoxic drugs combined with aerosolized colistin (OR = 15.03, 95% CI 1.40-161.76; p = 0.025) and septic shock (OR = 8.10, 95% CI 1.40-161.76; p = 0.04). Conclusions: The use of adjunctive aerosolized colistin treatment appears to be a relatively safe and effective option for the treatment of VAP caused by MDR-GNB. However, more research on the concomitant use of nephrotoxic drugs with aerosolized colistin will be necessary, as this can be an important risk factor of development of AKI.
참고문헌 (31)
- Hancock RE, "Peptide antibiotics", Lancet, 349, pp.418~422 (1997)
- Falagas ME, "Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections", Clin Infect Dis, 40, pp.1333~1341 (2005)
- Falagas ME, "Toxicity of polymyxins:a systematic review of the evidence from old and recent studies", Crit Care, 10, pp.R27~ (2006)
- Pogue JM, "Incidence of and risk factors for colistinassociated nephrotoxicity in a large academic health system", Clin Infect Dis, 53, pp.879~884 (2011)
- Hartzell JD, "Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center", Clin Infect Dis, 48, pp.1724~1728 (2009)
- Yapa SWS, "Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration", Antimicrob Agents Chemother, 58, pp.2570~2579 (2014)
- Jensen T, "Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection", J Antimicrob Chemother, 19, pp.831~838 (1987)
- Kollef MH, "Why is Acinetobacter baumannii a problem for critically ill patients?", Intensive Care Med, 41, pp.2170~2172 (2015)
- Bogović TZ, "Inhalation plus intravenous colistin versus intravenous colistin alone for treatment of ventilator associated pneumonia", Signa Vitae, 9(1), pp.29~33 (2014)
- Gurjar M, "Colistin for lung infection: an update", J Intensive Care, 3, pp.3~ (2015)
- Pogue JM, "Incidence of and risk factors for colistinassociated nephrotoxicity in a large academic health system", Clin Infect Dis, 53, pp.879~884 (2011)
- Kaye KS, "Principles and practice of infectious diseases", pp.435~436 (2005), Elsevier
- Horan TC, "CDC", NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting, 2008, pp.36, 309~332
- Korbila IP, "Inhaled colistin as adjunctive to intravenous colistin for the treatment of microbiologically documented VAP: a comparative cohort study", Clin Microbiol Infect, 16, pp.1230~1236 (2010)
- Knaus W, "APACHE II: a severity of disease classification system", Crit Care Med, 13, pp.818~829 (1985)
- Pugin J, "Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid", Am Rev Respir Dis, 143, pp.1121~1129 (1991)
- Kofteridis DP, "Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilatorassociated pneumonia: a matched case-control study", Clinical Infect Dis, 51, pp.1238~1244 (2010)
- Levey AS, "A New Equation to Estimate Glomerular Filtration Rate", Ann Intern Med, 150, pp.604~612 (2009)
- Bellomo R, "Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group", Crit Care, 8, pp.R204~R212 (2004)
- Hamer DH, "Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin", Am J Respir Crit Care Med, 162, pp.328~330 (2000)
- Evans ME, "Polymyxin B sulfate and colistin: old antibi-otics for emerging multiresistant gram-negative bacteria", Ann Pharmacother, 33, pp.960~967 (1999)
- DeRyke CA, "Colistin dosing and nephrotoxicity in a large community teaching hospital", Antimicrob Agents Chemother, 54, pp.4503~4505 (2010)
- Imberti R, "Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration", Chest, 138, pp.1333~1339 (2010)
- Steinfort DP, "Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis", Intern Med J, 37, pp.495~498 (2007)
- Marchand S, "Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys", Pharm Res, 32, pp.3404~3414 (2015)
- Sorlí L, "Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study", BMC Infect Dis, 13, pp.380~388 (2013)
- Katzmarzyk PT, "Body mass index and risk of cardiovascular disease, cancer and all-cause mortality", Can J Public Health, 103, pp.147~151 (2012)
- O’Brien JM Jr, "Excess body weight is not independently associated with outcome in mechanically ventilated patients with acute lung injury", Ann Intern Med, 140, pp.338~345 (2004)
- Hogue CW Jr, "The impact of obesity on outcomes after critical illness: a meta-analysis", Intensive Care Med, 35, pp.1152~1170 (2009)
- Arabi YM, "The Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: an international multicenter cohort study", Crit Care, 17, pp.R72~ (2013)
- Alothman GA, "Bronchial constriction and inhaled colistin in cystic fibrosis", Chest, 127, pp.522~529 (2005)